# US 10,577,591 B2 · Mumps virus as a potential oncolytic agent > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,577,591 B2 - Document ID: US10577591B2 - Status: Granted - Kind: B2 - Application number: 15/735,761 - Filed: 2016-06-10 - Published: 2018-07-05 - Granted: 2020-03-03 - Earliest claimed: 2015-06-12 - Assignees: Mayo Foundation for Medical Education and Research - Applicants: Mayo Foundation for Medical Education and Research - Inventors: Mark J. Federspiel; Arun Ammayappan; Gennett Pike; Stephen James Russell - Web page: https://patentgrep.com/patent/US10577591B2 ## CPC - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61K 39/12: Viral antigens - A61K 39/165: Mumps or measles virus - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61K 2039/525: {Virus} - C12N 2760/18721: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2760/18734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent. ## Claims ### Claim 1 A recombinant mumps virus (MuV) having oncolytic anti-cancer activity, wherein said recombinant MuV comprises nucleic acid encoding a modified RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10. ### Claim 2 (depends on 1) The recombinant MuV of claim 1, wherein said recombinant MuV is a replication competent MuV. ### Claim 3 (depends on 1) The recombinant MuV of claim 1, wherein said modification in an RNA polymerase L subunit coding sequence comprises an A to C substitution at nucleotide 13328 as numbered in SEQ ID NO: 1. ### Claim 4 A method for treating a patient having cancer, the method comprising: administering to the patient a recombinant mumps virus (MuV) having oncolytic anticancer activity, wherein said recombinant MuV comprises nucleic acid encoding a modified RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10. ### Claim 5 (depends on 4) The method of claim 4, wherein the cancer is a blood cancer selected from leukemia, lymphoma, or myeloma. ### Claim 6 (depends on 5) The method claim 5, wherein the blood cancer is myeloma. ### Claim 7 (depends on 4) The method of claim 4, wherein the cancer is a carcinoma selected from prostate cancer, breast cancer, hepatocellular carcinoma, lung cancer, or colorectal carcinoma. ### Claim 8 (depends on 7) The method of claim 7, wherein the carcinoma is colorectal carcinoma. ### Claim 9 (depends on 4) The method of claim 4, wherein said recombinant MuV is a replication competent MuV. ### Claim 10 (depends on 4) The method of claim 4, wherein said modification in an RNA polymerase L subunit coding sequence comprises an A to C substitution at nucleotide 13328 as numbered in SEQ ID NO:1. ### Claim 11 (depends on 4) The method of claim 4, further comprising administering ruxolitinib. ### Claim 12 An expression construct comprising a nucleotide sequence encoding a recombinant MuV having oncolytic anti-cancer activity, wherein said recombinant MuV comprises nucleic acid encoding a modified RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10. ### Claim 13 (depends on 12) The expression construct of claim 12, wherein said recombinant MuV is a replication competent MuV. ### Claim 14 (depends on 12) The expression construct of claim 12, wherein said modification in an RNA polymerase L subunit coding sequence comprises an A to C substitution at nucleotide 13328 as numbered in SEQ ID NO: 1. ### Claim 15 A method for treating a patient having cancer, the method comprising: administering to the patient an expression construct comprising a nucleotide sequence encoding a recombinant mumps virus (MuV) having oncolytic anti-cancer activity, wherein said recombinant MuV comprises nucleic acid encoding a modified RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10. ### Claim 16 (depends on 15) The method of claim 15, wherein the cancer is a blood cancer selected from leukemia, lymphoma, or myeloma. ### Claim 17 (depends on 16) The method claim 16, wherein the blood cancer myeloma. ### Claim 18 (depends on 15) The method of claim 15, wherein the cancer is a carcinoma selected from prostate cancer, breast cancer, hepatocellular carcinoma, lung cancer, or colorectal carcinoma. ### Claim 19 (depends on 18) The method of claim 18, wherein the carcinoma is colorectal carcinoma. ### Claim 20 (depends on 15) The method of claim 15, wherein said recombinant MuV is a replication competent MuV. ### Claim 21 (depends on 15) The method of claim 15, wherein said modification in an RNA polymerase L subunit coding sequence comprises an A to C substitution at nucleotide 13328 as numbered in SEQ ID NO: 1. ### Claim 22 (depends on 15) The method of claim 15, further comprising administering ruxolitinib.